$SLXN

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2026 results and said its SIL204 program moved into active Phase 2/3 for locally advanced pancreatic cancer. The company received Germany’s BfArM CTA approval and initiated the trial at Tel Aviv Sourasky Medical Center in late July. It also reported preclinical immune-sensitization data and closed a public offering with about $2.5M gross proceeds. Q2 R&D was ~$2.2M and net loss ~$3.6M.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering GRAND CAYMAN, Cayman Islands, August 11, 2026 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA inter

Silexion Therapeutics (SLXN) priced a $2.5 million public offering of 3.85 million ordinary shares and Series E warrants at $0.65 per share, with warrants exercisable at $0.65 and expiring in five years. Net proceeds will fund its Phase 2/3 SIL204 trial and general purposes. SLXN fell 31% to $1.03.

Silexion Therapeutics (NASDAQ: SLXN) reported new preclinical results for its SIL204 siRNA in KRAS-mutant pancreatic and NSCLC cell lines. SIL204 increased FAS (CD95) expression and decreased HLA-G, supporting a multi-pathway immune-sensitization rationale for combining with anti-PD-(L)1 therapies. The company is advancing SIL204 in Phase 2/3 after starting a first clinical trial site at Tel Aviv Sourasky Medical Center in late July 2026.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Resignation of Director On July 30, 2026, Professor Amnon Peled notified the Board of Directors (the “ Board ”) of Sile

Tel Aviv Sourasky Medical Center and Israeli biotech Silexion Therapeutics (Nasdaq: SLXN) announced a first-in-world clinical trial of SIL204, an siRNA therapy targeting KRAS mutations in pancreatic cancer. The study will enroll about 18 patients initially to assess safety, then expand, potentially to 166. SIL204 will be injected into tumors and combined with standard systemic treatment.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 12-31 0002022416 00-0000000 NASDAQ NASDAQ 0002022416 2026-07-21 2026-07-21 0002022416 slxn:OrdinarySharesParValue0135PerShareMember 2026-07-21 2026-07-21 0002022416 slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf1552500PerShareMember 2026-07-21 2026-07-21 UNITE

Silexion Therapeutics said Germany’s BfArM approved it to start a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, following a positive ethics opinion from the North Rhine Medical Association. The company also has Israel approval. Site activation is underway, with first patient dosing expected in the coming weeks.

Shirvan Mitchell, CSO and CDO of Silexion Therapeutics (SLXN), reported selling 22,818 Ordinary Shares on March 26, 2026, at $1.36 per share. This transaction was a "sale-to-cover" to address tax liabilities from a fully vested restricted share unit grant received in February 2026. Following the sale, Mitchell directly holds 27,889 Ordinary Shares and an adjusted stock option for 478 Ordinary Shares.